Jinquan Q Dong

US Patent:

20190008768, Jan 10, 2019

Filed:

Sep 14, 2018

Appl. No.:

16/131777

Inventors:

- Cambridge MA, US
Shyam B. Karki - Hillsborough NJ, US
Michael Kaufman - Lexington MA, US
Jinquan Dong - Stoneham MA, US
Ernest Quan - East Lyme CT, US
Kalyan Vasudevan - Cambridge MA, US

Assignee:

Biogen MA Inc. - Cambridge MA

International Classification:

A61K 9/00
A61K 31/22
A61K 9/50
A61K 9/48
A61K 9/28
A61K 9/20
A61K 9/14

Abstract:

A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

US Patent:

20160310419, Oct 27, 2016

Filed:

Dec 12, 2014

Appl. No.:

15/102306

Inventors:

- Cambridge MA, US
Shyam B. Karki - Hillsborough NJ, US
Michael Kaufman - Lexington MA, US
Jinquan Dong - Stoneham MA, US
Ernest Quan - East Lyme CT, US
Kalyan Vasudevan - Cambridge MA, US

International Classification:

A61K 9/00
A61K 9/14
A61K 9/20
A61K 9/50
A61K 9/48
A61K 31/22
A61K 9/28

Abstract:

A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.